Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the Primary Eradication of H.Pylori.

X
Trial Profile

A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the Primary Eradication of H.Pylori.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonoprazan (Primary) ; Amoxicillin; Clarithromycin; Lansoprazole
  • Indications Helicobacter pylori infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 02 Mar 2016 Results published in the Gut
    • 26 Mar 2015 According to a Takeda and Otsuka media release, Takeda submitted a NDA to the Ministry of Health, Labour and Welfare, Japan for a single pack containing drugs for the eradication of Helicobacter Pylori. One pack contains three drugs, vonoprazan fumarate, amoxicillin and clarithromycin for the first eradication, and other pack contains drugs, vonoprazan fumarate, amoxicillin and metronidazole for the second eradication of Helicobacter pylori.
    • 07 May 2014 According to a Takeda media release, the results of this trial will be presented at the Digestive Disease Week 2014.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top